25E-NBOH

2-(4-Ethyl-2,5-dimethoxyphenyl)-N-(2-hydroxybenzyl)ethanamine

2C-E-NBOH, NBOH-2C-E

Psychoactive Class

Chemical Class

25E-NBOH is a synthetic psychedelic of the substituted phenethylamine class, specifically an N-benzylated derivative of 2C-E.¹ It was first developed by Martin Hansen at the University of Copenhagen in 2010 for use as a brain imaging agent.² It has since appeared as a designer drug, first identified on seized blotter paper in Brazil in 2018.³ 25E-NBOH is reported to share most properties with 25E-NBOMe but with moderately reduced potency and a shorter duration.

Dosage & Duration

Dosage

Threshold~100 μg

Light100-600 μg

Moderate600-1000 μg

Strong1000-1200 μg

Heavy1200+ μg

Produces a strong, unpleasant metallic chemical taste and a distinct numbness of the tongue and mouth that can persist for up to an hour. Associated with a significant body load manifesting as vasoconstriction. Most samples found are not consistently dosed and are observed to have hotspots. It is highly advised to start at a lower dosage.

Duration

Onset15-45 minutes

Come Up30-60 minutes

Peak2-4 hours

Offset1-3 hours

After Effects1-12 hours

Total4-8 hours

Subjective Effects

25E-NBOH is a potent serotonergic psychedelic of the NBOH series, producing an experience in which visual effects tend to dominate over the headspace. As with related N-benzyl phenethylamines, users generally describe pronounced open- and closed-eye visuals accompanied by physical stimulation, with a mental state that is comparatively mild relative to the intensity of the sensory effects. Detailed first-hand documentation of this compound remains limited, and its full subjective profile is not well characterized.

Physical

The body experience is stimulating, and users of NBOH-series compounds commonly report physical tension alongside the energetic body feel.

Muscle tension

Cognitive

The headspace is generally described as lighter and less profound than that of classical psychedelics, with stimulation-tinged euphoria commonly reported.

Euphoria

Visual

Visual effects are the defining feature of the NBOH series and are reported as vivid and dose-dependent.

Distortions

Tracers

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)

Mecke(ME)

Mandelin(MD)

PROtestkit.eu

Pharmacology

Pharmacodynamics

In vitro, 25E-NBOH (compound 8b) bound human 5-HT2A receptors with a Ki of 0.29 nM and rat 5-HT2C receptors with a Ki of approximately 3.4 nM, corresponding to an 11.7-fold binding preference for 5-HT2A in that assay.² In human-receptor phosphoinositide-hydrolysis assays, its pEC50 values were 8.89 ± 0.10 at 5-HT2A and 7.42 ± 0.13 at 5-HT2C, with intrinsic activities of 94 ± 5% and 98 ± 2% of the serotonin response, respectively.² These in-vitro measurements do not establish a human dose-response or safety profile.

Pharmacokinetics

No controlled human pharmacokinetic profile has been published. However, metabolism is not wholly unknown: LC-HRMS molecular networking of plasma and urine from one severe intoxication involving both 25E-NBOH and MDPHP proposed seven 25E-NBOH metabolites—two phase I ions and five phase II ions.⁴ The authors reported M6 (m/z 492.223) as the most intense 25E-NBOH-related ion in both matrices and proposed it as a possible consumption marker.⁴ Because this was a single mixed-exposure case and the structures were proposed by molecular-networking evidence, the findings do not provide population pharmacokinetic parameters or definitive reference-standard confirmation of every metabolite.

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AMTLithiumPregabalin

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

AmphetaminesCocaineDXMTramadol

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

2C-T-x compounds2C-x compounds5-MeO-xxT tryptaminesCaffeineCannabisDiphenhydramineDOx compoundsMAOIsMDMAMescalineMXE

TripSit

Tolerance

Full Tolerance

Tolerance to the effects of 25E-NBOH develops almost immediately following ingestion.

Baseline Reset

2-4 days to return to baseline tolerance in the absence of further consumption.

Half Tolerance

Approximately 1-2 days for tolerance to reduce to half of its peak level.

Cross Tolerance

Serotonergic psychedelics (cross-tolerance is present but not uniform across all compounds; some psychedelics may be significantly affected while others experience only slight reduction in effects)

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Anecdotal reports suggest 25E-NBOH is non-habit-forming, consistent with classical psychedelics. The desire to use it may actually decrease with repeated use.

Toxicity

Cardiovascular

Acute cardiovascular effects including vasoconstriction, elevated blood pressure, and increased heart rate have been reported during intoxication; vasoconstriction contributes to the substance's notable body load, often manifesting as muscle soreness and tension.⁴⁵⁶

Psychosis Risk

Individuals with bipolar disorder or schizoaffective disorder are at elevated risk of experiencing a psychotic episode and are strongly advised to avoid this substance.

Seizure Risk

Seizures are rarely observed but represent a risk in predisposed individuals, particularly when combined with physically taxing conditions such as dehydration, fatigue, undernourishment, or overheating.

History & Culture

25E-NBOH was first synthesized in 2010 by Martin Hansen at the University of Copenhagen, where it was developed as a brain imaging agent for research purposes.² The compound was part of a broader effort to create selective serotonin receptor ligands suitable for…

Legality

By Country

United StatesUnscheduled (Analogue Act applies)

Not explicitly listed under the Controlled Substances Act of 1970. However, due to structural similarity to NBOMe-class compounds, it may be prosecuted under the Federal Analogue Act of 1986 when sold or possessed for human consumption, effectively treating it as a Schedule I substance.¹⁰ Manufacturing, purchasing, possessing, or distributing without DEA authorization could result in federal prosecution.

United KingdomClass A

Controlled under the Misuse of Drugs Act 1971 through the N-benzylphenethylamine catch-all clause, which covers structurally related compounds regardless of specific scheduling.⁸ Class A classification carries the most severe penalties under UK drug law, including up to seven years imprisonment for possession and life imprisonment for supply offenses.⁹

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 25E-NBOH article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.

25E-NBOH

2-(4-Ethyl-2,5-dimethoxyphenyl)-N-(2-hydroxybenzyl)ethanamine

2C-E-NBOH, NBOH-2C-E

Psychoactive Class

Psychedelic Hallucinogen

Chemical Class

Phenethylamine (N-benzylated)NBOH